ReviewInfectious diseases and therapy2026
Hepatitis A to E in People with HIV: A Virus-Specific Review of Prevention and Treatment.
Review in Infectious diseases and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
People with HIV (PWH) are disproportionately affected by viral hepatitis as a result of overlapping transmission routes, reduced vaccine immunogenicity, altered disease progression, and unique therapeutic considerations under HIV-related immunosuppression. Although the scale-up of antiretroviral therapy (ART) and direct-acting antivirals (DAAs) has significantly improved outcomes, viral hepatitis remains a major cause of liver-related morbidity and mortality in this population. This virus-specific review summarizes current knowledge and recent advances in the epidemiology, vaccination, and treatment strategies for hepatitis A through E (i.e., hepatitis A virus (HAV), hepatitis B virus (HBV), hepatitis C virus (HCV), hepatitis D virus (HDV), and hepatitis E virus (HEV); HAV-HEV) among PWH. HAV has re-emerged in community outbreaks among men who have sex with men (MSM), with prolonged or atypical presentations in people who are immunocompromised, underscoring the need for improved vaccination coverage and durable immunity. HBV coinfection remains the most clinically significant challenge, requiring lifelong dual-active ART and raising persistent concerns about poor vaccine response and long-term protection. HCV has become curable with DAAs, yet reinfection-particularly among MSM and people who inject drugs-remains a major barrier to microelimination. HDV, though less prevalent, causes severe liver disease and now has promising targeted therapies under clinical use or investigation. HEV is increasingly recognized as an underdiagnosed pathogen and potentially chronic infection in people who are immunocompromised, with limited diagnostic availability and global accessibility to effective vaccine. Effective hepatitis prevention and treatment in PWH must address the immunologic, clinical, and virologic nuances of each virus. Integrated models of care that combine HIV and hepatitis services are essential to improving long-term liver health, reducing disparities, and advancing toward global goals of viral hepatitis elimination.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.